Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%

Follow NBIX

Alert me

Market cap: $16.2B
P/E: 23.0×
Fwd P/E: 20.6×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a P/B ratio of 4.2×. Over the past ten years it has ranged from 3.4× (April 2025) to 30.0× (September 2018); the current reading is higher than 5% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/NBIX/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Neurocrine Biosciences, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/NBIX/metrics/pb-ratio">Neurocrine Biosciences, Inc. (NBIX) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	4.3×	(18.03%)
FY2024	5.3×	(8.22%)
FY2023	5.8×	(14.40%)
FY2022	6.7×	14.87%
FY2021	5.9×	(25.99%)
FY2020	7.9×	(48.75%)
FY2019	15.5×	15.39%
FY2018	13.4×	(28.63%)
FY2017	18.8×	76.31%
FY2016	10.6×	(5.46%)

Period	P/B ratio	Change
Sep 2026	3.7×	(19.38%)
Jun 2026	4.6×	18.61%
Mar 2026	3.9×	(10.43%)
Dec 2025	4.3×	(6.62%)
36 more quarters	Free account

Against its own ten years

Low 3.4× High 30.0×

Ten-year median 7.6×

Current reading's percentile 5

Company	P/B ratio
VTRS Viatris Inc. compare	1.6×
ELAN Elanco Animal Health Incorporated compare	1.8×
HLN Haleon PLC Sponsored ADR compare	1.9×
RDY Dr. Reddy's Laboratories Ltd compare	3.0×
UTHR United Therapeutics Corporation compare	3.8×
ALKS Alkermes plc compare	4.0×
NBIX Neurocrine Biosciences, Inc.	4.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	9.7×
ZTS Zoetis Inc. compare	10.8×
Drug Manufacturers Specialty & Generic industry median	1.8×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Neurocrine Biosciences, Inc. (NBIX) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on NBIX

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on NBIX

Stockrow Weekly